Preventive Migraine Treatment: Newer Perspective
Sandhya Manorenj*
Department of Neurology, Princess Esra Hospital, Deccan College of Medical Sciences, Hyderabad, India.
*Corresponding Author: Dr Sandhya Manorenj, MBBS, DNB (Gen Medicine), DNB (Neurology), MRCP SCE Neurology, FEBN, FRCP (London), Professor and Head, Department of Neurology, Princess Esra Hospital, Deccan College of Medical Sciences, Hyderabad, Telangana, India.
https://doi.org/10.58624/SVOANE.2025.06.028
Received: November 03, 2025
Published: November 26, 2025
Citation: Manorenj S. Preventive Migraine Treatment: Newer Perspective. SVOA Neurology 2025, 6:6, 167-175. doi. 10.58624/SVOANE.2025.06.028
Abstract
Background: Preventive management of migraine aims to diminish attack frequency, duration, and severity through pharmacologic and non-pharmacologic strategies.
Methods: Articles published between 2001 and June 2024 concerning migraine prevention were systematically reviewed.
Results: Current guidelines advocate preventive therapy for frequent or disabling migraines. Evidence supports beta-blockers, antiepileptics, antidepressants, and CGRP-targeted agents. Recent innovations include gepants, monoclonal antibodies, botulinum toxin, and neuromodulation devices.
Conclusion: CGRP-targeted therapies represent a major advance, recommended as first-line options alongside established pharmacologic and lifestyle interventions.
Keywords: Migraine prevention, CGRP-targeted therapy, Preventive treatment, Neuromodulation
